1887

Abstract

The emergence of metallo-β-lactamase (MBL)-producing , mainly New Delhi metallo-β-lactamase (NDM), represents a clinical threat due to the limited therapeutic alternatives. Aztreonam (AZT) is stable to MBLs, but most MBL-producing isolates usually co-harbour other β-lactamases that confer resistance to AZT and, consequently, its use is restricted in these isolates. We compared the ability of sulbactam (SUL), tazobactam (TAZ), clavulanic acid (CLA) and avibactam (AVI) to restore the AZT activity in MBL-producing AZT-resistant isolates. A collection of 64 NDM-producing AZT-resistant from five hospitals in Buenos Aires city, Argentina, were studied during the period July–December 2020. MICs were determined using the agar dilution method with Mueller–Hinton agar according to Clinical and Laboratory Standards Institute (CLSI) recommendations. AVI, SUL and TAZ were used at a fixed concentration of 4 mg l, whereas CLA was used at a fixed concentration of 2 mg l. A screening method based on disc diffusion to evaluate this synergy was also conducted. Detection of , , , , and was performed by PCR. The AZT-AVI combination restored the AZT activity in 98.4 % of AZT-resistant strains, whereas CLA, TAZ and SUL did so in 70.3, 15.6 and 12.5 %, respectively, in isolates co-harbouring extended-spectrum β-lactamases, but were inactive in isolates harbouring AmpC-type enzymes and/or KPC. The synergy screening test showed an excellent negative predictive value to confirm the absence of synergy, but positive results should be confirmed by a quantitative method. The excellent performance of the AZT-CLA combination represents a much more economical alternative to AZT-AVI, which could be of use in the treatment of MBL-producing, AZT-resistant .

Funding
This study was supported by the:
  • Secretaria de Ciencia y Tecnica, Universidad de Buenos Aires (Award UBACyT 20020130100167BA)
    • Principle Award Recipient: AngelaFamiglietti
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001427
2021-10-04
2021-10-17
Loading full text...

Full text loading...

References

  1. Jee Y, Carlson J, Rafai E, Musonda K, Huong TTG et al. Antimicrobial resistance: a threat to global health. Lancet Infect Dis 2018; 18:939–940 [View Article] [PubMed]
    [Google Scholar]
  2. Cejas D, Fernandez Caniggia L, Nastro M, Rodríguez C, Tanco A et al. Hyperendemic clone of KPC producing Klebsiella pneumoniae ST 258 in Buenos Aires hospitals. Infect Genet Evol 2012; 12:499–501 [View Article] [PubMed]
    [Google Scholar]
  3. Cejas D, Elena A, Guevara Nuñez D, Sevillano Platero P, De Paulis A et al. Changing epidemiology of KPC-producing Klebsiella pneumoniae in Argentina: emergence of hypermucoviscous ST25 and high-risk clone ST307. J Glob Antimicrob Resist 2019; 18:238–242 [View Article] [PubMed]
    [Google Scholar]
  4. Dortet L, Poirel L, Nordmann P. Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. Biomed Res Int 2014; 2014:249856 [View Article] [PubMed]
    [Google Scholar]
  5. Cantón R, Gijón D, Ruiz-Garbajosa P. Antimicrobial resistance in ICUs: an update in the light of the COVID-19 pandemic. Curr Opin Crit Care 2020; 26:433–441 [View Article] [PubMed]
    [Google Scholar]
  6. Falcone M, Daikos GL, Tiseo G, Bassoulis D, Giordano C et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL-producing Enterobacterales. Clin Infect Dis 2020; 19:1871–1878 [View Article]
    [Google Scholar]
  7. Zou C, Wei J, Shan B, Chen X, Wang D et al. In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against carbapenem-resistant enterobacteriaceae isolates collected from three secondary hospitals in southwest china between 2018 and 2019. Infect Drug Resist 2020; 13:3563–3568 [View Article] [PubMed]
    [Google Scholar]
  8. Falcone M, Paterson D. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother 2016; 7:2713–2722 [View Article]
    [Google Scholar]
  9. Emeraud C, Escaut L, Boucly A, Fortineau N, Bonnin RA et al. Aztreonam plus clavulanate, tazobactam, or avibactam for treatment of infections caused by metallo-β-lactamase-producing gram-negative bacteria. Antimicrob Agents Chemother 2019; 63:e00010-19 [View Article] [PubMed]
    [Google Scholar]
  10. CLSI Performance Standards for Antimicrobial Susceptibility Testing, supplement M100, 30th edn Wayne, PA: Clinical and Laboratory Standards Institute; 2020
    [Google Scholar]
  11. CLSI Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, standard M07, 11th edn Wayne, PA: Clinical and Laboratory Standards Institute; 2018
    [Google Scholar]
  12. EUCAST Setting Breakpoints for New Antimicrobial Agents, EUCAST SOP 1.1 Basel: European Committee on Antimicrobial Susceptibility Testing; 2020
    [Google Scholar]
  13. Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis 2011; 70:119–123 [View Article] [PubMed]
    [Google Scholar]
  14. Biagi M, Wu T, Lee M, Patel S, Butler D et al. Searching for the optimal treatment for metallo- and serine-β-lactamase producing enterobacteriaceae: aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam. Antimicrob Agents Chemother 2019; 63:e01426–19 [View Article] [PubMed]
    [Google Scholar]
  15. Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM et al. Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in enterobacteriaceae?. Antimicrob Agents Chemother 2017; 61:e02243-16 [View Article] [PubMed]
    [Google Scholar]
  16. Ruggiero M, Papp-Wallace KM, Brunetti F, Barnes MD, Bonomo RA et al. Structural insights into the inhibition of the extended-spectrum β-lactamase per-2 by avibactam. Antimicrob Agents Chemother 2019; 63:e00487-19 [View Article] [PubMed]
    [Google Scholar]
  17. Quinteros M, Radice M, Gardella N, Rodriguez MM, Costa N et al. Extended-spectrum beta-lactamases in enterobacteriaceae in Buenos Aires, Argentina, public hospitals. Antimicrob Agents Chemother 2003; 47:2864–2867 [View Article] [PubMed]
    [Google Scholar]
  18. Xu Q, Fu Y, Ji J, Du X, Yu Y. In vitro effect of the combination of aztreonam and amoxicillin/clavulanic acid against carbapenem-resistant gram-negative organisms producing metallo-β-lactamase. Infect Drug Resist 2021; 14:833–839 [View Article] [PubMed]
    [Google Scholar]
  19. Rocha-Santos G, Cuba GT, Cayô R, Streling AP, Nodari CS et al. In vitro synergy of ticarcillin/clavulanate in combination with aztreonam and ceftolozane/tazobactam against SPM-1-producing Pseudomonas aeruginosa strains. Diagn Microbiol Infect Dis 2021; 100:115343 [View Article] [PubMed]
    [Google Scholar]
  20. Biagi M, Lamm D, Meyer K, Vialichka A, Jurkovic M et al. Activity of aztreonam in combination with avibactam, clavulanate, relebactam, and vaborbactam against multidrug-resistant Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2020; 64:e00297–20 [View Article] [PubMed]
    [Google Scholar]
  21. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Antimicrobial wild type distributions of microorganisms; 2021 https://mic.eucast.org/search/?search%5Bmethod%5D=mic&search%5Bantibiotic%5D=14&search%5Bspecies%5D=-1&search%5Bdisk_content%5D=-1&search%5Blimit%5D=50
  22. García J, Nastro M, Cejas D, Santana G, Mancino MB et al. Emergence of ceftazidime/avibactam resistance in KPC-8-producing Klebsiella pneumoniae in South America. Clin Microbiol Infect 2020; 26:1264–1265 [View Article] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001427
Loading
/content/journal/jmm/10.1099/jmm.0.001427
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error